Global Long Read Sequencing Market Size to Reach USD 12,294.7 Million by 2033 | Growing at a CAGR of 34.7%

Market Overview

The global long read sequencing market size was valued at USD 672.9 Million in 2024. The market is projected to reach USD 12,294.7 Million by 2033, growing at a CAGR of 34.7% between 2025 and 2033. Long read sequencing (LRS) improves genome assembly and mapping and eliminates amplification bias while preserving base modifications. Its broad applications in genomics, combined with increased acceptance in medical diagnostics and portability, are driving market growth. 

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Long Read Sequencing Market Key Takeaways

• Current Market Size: USD 672.9 Million in 2024
• CAGR: 34.7% during 2025-2033
• Forecast Period: 2025-2033
• Long read sequencing improves de novo assembly, mapping certainty, and detection of structural variants while preserving base modifications.
• LRS technology offers higher-quality genome assemblies and better characterization of genetic variation than next-generation sequencing.
• Rising cases of genetic disorders and acceptance of modern diagnostics are major market drivers.
• Portability and real-time speed of LRS technology boost demand.
• Multiple biotech companies are innovating with new library prep methods and genome analysis tools.
• Increased use in whole-genome sequencing and medical genetics presents expanded research opportunities.

Request for a Free Sample Report: https://www.imarcgroup.com/long-read-sequencing-market/requestsample

Market Growth Factors

The escalating number of individuals suffering from genetic disorders and the increasing acceptance of modern diagnostic approaches are crucial factors propelling the global long read sequencing market. LRS technology enhances the detection of pathogenic mutations in diseases with unknown genetic causes, thus offering invaluable tools for medical diagnostics and genomics research. These capabilities are fueling market growth by addressing unmet clinical and research needs.

Another growth driver is the inherent portability and real-time speed of long read sequencing technology. Unlike traditional sequencing methods, LRS can deliver rapid, high-quality genome assemblies that capture clinically relevant genomic elements. This efficiency supports both medical and research applications, attracting broader adoption in healthcare and academic institutions, thereby expanding market demand.

Furthermore, ongoing innovations by biotech companies developing novel library preparation methods and genome analysis tools are stimulating market expansion. The rising investment in R&D activities and the increasing utilization of sequence analysis methodologies in academic and medical institutes are expected to accelerate LRS technology adoption. These advancements enhance the technology's applicability and open new avenues for genomic discoveries.

Market Segmentation

IMARC Group has segmented the global long read sequencing market report based on technology, product, application, and end use as follows:

Breakup by Technology:

• Single-Molecule Real-Time Sequencing (SMRT): This technology enables long read sequencing through single-molecule analysis, offering accurate genomic assemblies.
• Nanopore Sequencing: Utilizes nanopore technology to sequence DNA/RNA by detecting changes in electric current as molecules pass through nanopores.

Breakup by Product:

• Instruments: Devices and hardware required for conducting long read sequencing.
• Consumables: Reagents and materials consumed during the sequencing process.
• Others: Additional related products supporting sequencing workflows.

Breakup by Application:

• Whole Genome Sequencing: Comprehensive sequencing of the entire genome using LRS.
• Epigenetics: Study of chemical modifications on DNA and associated gene expression using sequencing.
• RNA Sequencing: Analysis of RNA sequences to study transcriptomes.
• Targeted Sequencing: Sequencing of specific genome regions of interest.
• Others: Additional sequencing applications beyond those listed.

Breakup by End Use:

• Academic and Research Institutes: Use of LRS technology for research and educational purposes.
• Hospitals and Clinics: Application of sequencing in clinical diagnostics and patient care.
• Pharma and Biotech Companies: Utilization for drug development and biotechnology research.
• Others: Other entities using LRS technology.

Regional Insights

North America emerges as the dominant region in the global long read sequencing market. Key countries include the United States and Canada. The region benefits from advanced healthcare infrastructure, significant R&D investment, and early adoption of LRS technologies. Specific market share and CAGR statistics are not provided in the source, but the region is emphasized as leading in growth and adoption.

Key Players

• BaseClear B.V.
• Future Genomics Technologies B.V.
• Genexa AG
• MicrobesNG
• Oxford Nanopore Technologies Limited
• Pacific Biosciences of California Inc.
• Promega Corporation
• Quantapore Inc.
• Roche Sequencing (F. Hoffmann-La Roche AG)
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask Our Expert & Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=3408&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302